KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Equity (2018 - 2025)

Historic Return on Equity for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to 0.24%.

  • Esperion Therapeutics' Return on Equity rose 1300.0% to 0.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.24%, marking a year-over-year increase of 1300.0%. This contributed to the annual value of 0.01% for FY2024, which is 5400.0% down from last year.
  • Latest data reveals that Esperion Therapeutics reported Return on Equity of 0.24% as of Q3 2025, which was up 1300.0% from 0.25% recorded in Q2 2025.
  • Esperion Therapeutics' Return on Equity's 5-year high stood at 1.13% during Q2 2021, with a 5-year trough of 0.01% in Q4 2024.
  • For the 5-year period, Esperion Therapeutics' Return on Equity averaged around 0.59%, with its median value being 0.65% (2023).
  • Within the past 5 years, the most significant YoY rise in Esperion Therapeutics' Return on Equity was 60700bps (2021), while the steepest drop was -167500bps (2021).
  • Quarter analysis of 5 years shows Esperion Therapeutics' Return on Equity stood at 0.98% in 2021, then decreased by -22bps to 0.76% in 2022, then tumbled by -35bps to 0.5% in 2023, then crashed by -97bps to 0.01% in 2024, then skyrocketed by 1806bps to 0.24% in 2025.
  • Its Return on Equity stands at 0.24% for Q3 2025, versus 0.25% for Q2 2025 and 0.26% for Q1 2025.